Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5745 plus mFOLFOX6 versus placebo plus mFOLFOX6 in first-line advanced gastric or gastroesophageal junction adenocarcinoma
2015-001526-42Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing GS-5745 plus mFOLFOX6 with Placebo plus mFOLFOX6 (2 arms). Primary endpoint: Overall survival. Started Feb 2016; status: completed.
02
Drugs
andecaliximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2015-001526-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001526-42.